SBT8230 Antibody
SBT8230 Antibody is the antibody moiety of SBT8230, and belongs to anti-ASGR1 antibodies. SBT8230 is an ASGR1-targeted TLR8 agonist, which acts as an ASGR1-TLR8 immune-targeting antibody conjugate (ISAC). SBT8230 activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. The isotype control for SBT8230 Antibody is Human IgG1 kappa, Isotype Control (HY-P99001).
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
|
TLR8 |
In Vitro
SBT8230 Antibody is the antibody component of SBT8230. As a liver-targeted TLR8 agonist against ASGR1, SBT8230 activates myeloid cells in hepatocyte models and induces anti-HBV immune responses and antiviral T-cell responses[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Gene ID
Accession
Target
ASGR1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Gan L, et al. A High-Throughput Cell-Based Luciferase Reporter Assay for Identifying Inhibitors of ASGR1. Int J Mol Sci. 2025;26(10):4590. Published 2025 May 10. [Content Brief]
[2]. Mak LY, et al. New strategies for the treatment of chronic hepatitis B. Trends Mol Med. 2022;28(9):742-757. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SBT8230 Antibody Related Classifications
HY-P992458 Related Classifications
Powered by Bioz